Harrow Health Overview
- Harrow Health, Inc. is a publicly traded pharmaceutical company (Nasdaq:HROW) based in Nashville, TN.
- Harrow Health started six healthcare businesses since 2014, including ImprimisRx, Eton Pharmaceuticals, Surface Pharmaceuticals, and Melt Pharmaceuticals.
- Harrow Health hired Drew Livingston as its Chief Innovation Officer in 2019.
- Harrow Health's subsidiary, Visionology.com, focuses on telemedicine.
- Harrow Health is known for its advocacy for drug pricing and patient access to affordable medication.

Administration and Drug Pricing Advocacy
- Mark L. Baum is the founder and CEO of Harrow Health, with a background in law.
- Baum has been working in the HIV-related pharmacy field since 1999.
- Baum has been an advocate for drug pricing and patient advocacy, including debating former US congressman James Greenwood on this issue.
- Harrow Health, through its ImprimisRx subsidiary, aims to create competition for monopolised drugs by marketing new formulations as a compounding pharmacy.
- Harrow Health gained attention for offering low-cost alternatives to expensive medications, such as a $1 per pill alternative to Daraprim.

ImprimisRx Compounding Business
- ImprimisRx is Harrow Health's compounding subsidiary.
- ImprimisRx was the first compounding company to offer cGMP ophthalmic eye drops and other sterile compounded products at a national scale.
- ImprimisRx's primary business is compounding drugs to market them to specific populations.
- ImprimisRx focuses on developing and selling inexpensive alternatives to off-patent medicines.
- ImprimisRx expanded its business to include the sale of FDA-approved steroid product called Dexycu through a partnership with EyePoint Pharmaceuticals.

Litigation
- Harrow Health (then Imprimis Pharmaceuticals) faced a lawsuit from Allergan for alleged false and misleading marketing statements.
- Allergan was accused of engaging in significant lobbying to complain about ImprimisRx.
- In 2017, ImprimisRx received a warning letter from the FDA regarding false or misleading claims about efficacy and risks in their eye drops.
- After a jury trial, Harrow was ordered to pay $0 for disgorgement of profit and $48,500 for lost profit, despite Allergan seeking $60 million.
- The lawsuit highlighted the power dynamics between a small pharmaceutical company like Imprimis and a large company like Allergan.

External Links and References
- Harrow Health's accomplishments and activities have been covered by various news outlets, including The Wall Street Journal, Forbes, and USA TODAY.
- ImprimisRx's low-cost alternatives to expensive drugs gained international attention.
- Harrow Health's CEO, Mark L. Baum, has written about drug pricing and monopolies in his monograph and has spoken at the Oxford Union debating society.
- Harrow Health's subsidiaries, Eton Pharmaceuticals and Surface Pharmaceuticals, have received significant funding for their operations.
- Harrow Health's Visionology.com subsidiary focuses on telemedicine and improving access to healthcare services.